MDACC Study No:2010-0486 ( NCT No: NCT01187199)
Title:Phase I Trial of Bevacizumab and Temsirolimus in Combination with 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer
Principal Investigator:Shannon Westin
Treatment Agent:Avastin; Carboplatin; Paclitaxel; Sorafenib; Temsirolimus
Study Status:Open
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of the combination of bevacizumab (Avastin) and temsirolimus (Torisel) that can
be given with 1 of 3 other study drugs --carboplatin (Paraplatin), paclitaxel
(Taxol), or sorafenib (Nexavar). The safety of these drug combinations will
also be studied.
Hide details for General InformationGeneral Information

Disease Group:Advanced Cancers
Phase of Study:Phase I
Treatment Agents:Avastin
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:N/A
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Shannon Westin
Dept:Investigational Cancer Therapeutics
For Clinical Trial Enrollment:713-563-1930
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults